GIO World Health Business Combination with Apeiron Capital Investment Corp.

Winston & Strawn is representing GIO World Health, a recently formed company focused on stem cell research and development, in its announced business combination with Apeiron Capital Investment Corp. (OTC: APNC), a publicly traded special purpose acquisition company. Upon closing, GIO World Health will become public in order to bring its proprietary stem cell treatments to market and other stem cell-based products for global consumption. The parties intend that at the closing of the proposed transaction, Apeiron Capital common stock will be listed on either the NYSE or NASDAQ, and Apeiron Capital will be renamed “GIO World Health Holdings, Inc.” Under the business combination agreement (BCA), Apeiron Capital will acquire shares of GIO World Health from its existing shareholders in exchange for newly issued common shares of Apeiron Capital. GIO shareholders holding approximately 98.7% of its outstanding shares have signed on to sell their shares to Apeiron Capital under the BCA, and the parties intend to have the remaining GIO shareholders participate in the transaction prior to the closing. Under the terms of the BCA, GIO World Health is valued at a pre-money enterprise value of US$250M.